Condensed Consolidated Statements of Cash Flows (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss	$ (2,376)	$ (3,224)
Adjustments to reconcile net loss to net cash used for operating activities:
Depreciation and amortization	365	663
Amortization of debt discount and deferred financing costs	29	0
Stock-based employee compensation	376	613
Restricted stock expense	2	3
Series C Preferred Shares issued for services	0	195
Series C Preferred issued in settlement of indemnity claim	417	0
Common Stock received as settlement of 16b claim	(325)	0
Warrants issued for services	3	0
(Gain) loss on derivative liability	(149)	(24)
Forfeiture of restricted stock issued in lieu of salary	0	(16)
Changes in operating assets and liabilities:
Accounts receivable, net	(216)	(452)
Prepaid expenses and other assets	(165)	12
Accounts payable	75	(197)
Accrued Compensation	76	(197)
Other accrued liabilities	(37)	39
Deferred revenue	(136)	(161)
Net cash used in operating activities	(2,061)	(2,746)
Cash flows from investing activities:
Acquisition of property and equipment	(8)	(13)
Capitalized software development costs	0	(72)
Net cash used in investing activities	(8)	(85)
Cash flows from financing activities:
Net proceeds from issuance of Series C preferred shares	0	686
Net proceeds from issuance of short-term debt	2,328	600
Proceeds from exercise of warrants for cash	213	0
Proceeds from exercise of stock options	12	0
Payment of short-term debt	(225)	0
Net cash provided by financing activities	2,328	1,286
Effect of exchange rate changes on cash and cash equivalents	0	0
Net decrease in cash and cash equivalents	259	(1,545)
Cash and cash equivalents at beginning of period	307	1,879
Cash and cash equivalents at end of period	566	334
Supplemental disclosure of cash flow information:
Interest paid	0	0
Income tax paid	0	0
Non-cash financing and investing transactions:
Series C preferred shares issued in separation agreement	0	36
Dividends on preferred shares	491	796
Accretion of beneficial conversion feature on Preferred Shares	968	929
Cashless exercise of warrants	202	0
Conversion of Series B Preferred Stock into Common Stock	140	0
Conversion of Series C Preferred Stock into Common Stock	$ 39	$ 0